Sunday, August 28, 2016
MammaPrint Finds Breast Cancer Patients Who Can Skip Chemo
In breast cancer patients who were judged to be at high risk by clinical assessment, and who were thus destined for chemotherapy, use of the 70-gene signature test (MammaPrint, Agendia) found that half (49%) of these women could skip chemotherapy.
This finding comes from the large European study called MINDACT (Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy), which was published online August 25 in the New England Journal of Medicine.
These results were first presented at the 2016 annual meeting of the American Association for Cancer Research and were reported at the time by Medscape Medical News.
In the critical group of patients at high clinical risk but at low genomic risk, as identified with MammaPrint, the use of adjuvant chemotherapy was associated with a 5-year survival rate without distant metastasis that was 1.5% higher in comparison with patients who did not receive adjuvant chemotherapy — 95.9% vs 94.4%. Corresponding rates of 5-year disease-free survival and overall survival were also higher — 2.8% and 1.4%, respectively. The study was not powered to determine significance between the groups, but the magnitude of chemotherapy benefit appeared modest in consideration of its inconvenience, risks, and costs, the researchers note.
"The study confirms that it is possible to identify patients who are not going to benefit from adjuvant chemotherapy in a significant way," co–principal investigator of MINDACT Martine Piccart, MD, PhD, head of the Department of Medicine at the Jules Bordet Institute in Brussels, and cofounder and chair of the Breast International Group, told Medscape Medical News.